Decreased levels of circulating CD34(+) cells are associated with coronary heart disease in Japanese patients with type 2 diabetes

日本2型糖尿病患者循环CD34(+)细胞水平降低与冠心病相关

阅读:1

Abstract

AIMS/INTRODUCTION: Circulating progenitor cells, including CD34 positive (CD34(+)) cells, play a key role in neovascularisation and the maintenance of vascular endothelial function. Several lines of evidence show an association between decreased levels of circulating CD34(+) cells and cardiovascular disease. However, the contribution of circulating CD34(+) cells to the occurrence of cardiovascular events in diabetic patients remains unclear. MATERIALS AND METHODS: In the present study with a median follow up of 4.6 years, we analyzed the level of circulating CD34(+) cells in 192 patients with type 2 diabetes. The outcome variables were coronary heart disease (CHD) events (cardiovascular death, unstable angina, myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting) and cerebrovascular disease events (cerebral infarction, cerebral hemorrhage or transient ischemic attack). RESULTS: Decreased levels of circulating CD34(+) cells were associated with a significantly higher incidence of CHD based on Kaplan-Meier analysis (P = 0.0052). After adjusting for age, sex, dyslipidemia, hypertension, glycated hemoglobin, history of cardiovascular disease, body mass index, and statin and renin angiotensin system inhibitors use, decreased levels of CD34(+) cells were significantly associated with the incidence of CHD events (hazard ratio of low tertile 2.61, 95% confidence interval 1.22-5.96; P = 0.013, reference; high tertile). CONCLUSIONS: Decreased levels of circulating CD34(+) cells might predict CHD events in patients with diabetes, and this could be useful for identifying patients with diabetes at high risk of cardiovascular events.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。